FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors - FDA Press Releases

FDA approved Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation

from FDA Press Releases RSS Feed https://ift.tt/2FAShnf
via IFTTT